Breckenridge announced today that it has entered into another separate agreement with Helm AG to develop and manufacture an ANDA for an asthma drug product. Under terms of this new agreement, Breckenridge will submit an ANDA to the U.S. Food and Drug Administration (FDA) in 2009 for the product which is in development by Helm AG. The product currently shows U.S. sales of approximately $4 billion, and is patent protected until 2012.
The details can be read here.
No comments:
Post a Comment